Immuron Travelan® Global sales up 216%
April 27, 2022 06:00 ET
|
Immuron Limited
Key Highlights: North American Travelan® sales up by 185% YoY in Q3 FY22Global sales up 216% YoY in Q3 FY22.YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing 340% YoY. ...
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
April 19, 2022 07:33 ET
|
Immuron Limited
Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...
Appointment of Paul Brennan as Non-Executive Director
March 16, 2022 09:30 ET
|
Immuron Limited
MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives AUD $306,154 R&D Tax Concession Refund
January 17, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
January 13, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
January 12, 2022 06:00 ET
|
Immuron Limited
Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for TravelanU.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to...
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
November 15, 2021 06:00 ET
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC...
US DoD Naval Medical Research Center Clinical Update
November 10, 2021 06:00 ET
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration...
IMM-124E – Demonstrates Antiviral T-Cell Immunity
October 08, 2021 06:00 ET
|
Immuron Limited
Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical...
Immuron Director resignation
September 23, 2021 23:00 ET
|
Immuron Limited
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...